Molecule Information

General Information of the Molecule (ID: Mol02148)

• Name: GTPase HRas (HRAS) ,Mus musculus
• Synonyms: Hras Hras1
• Molecule Type: Protein
• Gene Name: Hras
• Gene ID: 15461
• Location: chr7:140,769,018-140,773,918[-]
• Sequence:
  MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAG
  QEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDL
  AARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPG
  CMSCKCVLS
• Function: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
• Uniprot ID: RASH_MOUSE
• Ensembl ID: ENSMUSG00000025499

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: 9989
Family: Muridae
Genus: Mus
Species: Mus musculus

Type(s) of Resistant Mechanism of This Molecule

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Investigative Drug(s) 2 drug(s) in total

GDC-0623

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Unclassified pleomorphic sarcoma [1]

• Resistant Disease: Unclassified pleomorphic sarcoma [ICD-11: 2B54.0]
• Resistant Drug: GDC-0623
• Molecule Alteration: Missense mutation; p.G12V
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: RAS signaling pathway; Activation; hsa04014
• In Vitro Model: HEK293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• In Vitro Model: NIH3T3 cells; Embryo; Homo sapiens (Human); N.A.
• In Vivo Model: SCID/Beige mice model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; Western blotting assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Hras G12V mutation changed the drug target,impairing the ability to inhibit RAS-RAF-MEK-ERK signaling.

SCH772984

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Unclassified pleomorphic sarcoma [1]

• Resistant Disease: Unclassified pleomorphic sarcoma [ICD-11: 2B54.0]
• Resistant Drug: SCH772984
• Molecule Alteration: Missense mutation; p.G12V
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: RAS signaling pathway; Activation; hsa04014
• In Vitro Model: HEK293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• In Vitro Model: NIH3T3 cells; Embryo; Homo sapiens (Human); N.A.
• In Vivo Model: SCID/Beige mice model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; Western blotting assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Hras G12V mutation changed the drug target,impairing the ability to inhibit RAS-RAF-MEK-ERK signaling.

References

• Ref 1: Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition .Cancers (Basel). 2021 Apr 13;13(8):1852. doi: 10.3390/cancers13081852. 10.3390/cancers13081852